Cancer
ESR1 Mutations in Breast Cancer
Dustin D, Gu G, Fuqua SAW
In this review, the authors discuss mechanisms of resistance and dissemination of ESR1 mutations. They also review detection methods for ESR1 mutation tracking, newly discovered potential therapeutic targets, and clinical implications and treatment options for treating patients with ESR1-mutant tumors.
Previous Article
- • Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
- • Imlunestrant Monotherapy: Phase 1a/1b EMBER Study
- • Characterization of Imlunestrant as an Oral, Brain-Penetrant SERD
- • Pharmacodynamics from EMBER-2
- • Imlunestrant: First Approval
- • Imlunestrant Overcomes ESR1 Mutant Resistance in ER-Positive Breast Cancer
- • ESR1 Mutations in Breast Cancer
